Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice
about
Gadd45 stress sensors in malignancy and leukemiaEngineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?(1)H NMR studies distinguish the water soluble metabolomic profiles of untransformed and RAS-transformed cellsPalmitoylation of oncogenic NRAS is essential for leukemogenesis.NRAS mutations are rare in colorectal cancer.Nras overexpression results in granulocytosis, T-cell expansion and early lethality in mice.Induction of histiocytic sarcoma in mouse skeletal muscle.Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1RKRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations.Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2Modelling oncogenic Ras/Raf signalling in the mouse.Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cellsA New View of Ras Isoforms in Cancers.Targeting oncogenic Ras signaling in hematologic malignancies.Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4ADifferential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer.Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.The role of wild type RAS isoforms in cancer.The epigenetically-regulated miR-663 targets H-ras in K-562 cells.Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model.Tumour maintenance is mediated by eNOS.VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.Functional specificity of ras isoforms: so similar but so different.Rare codons regulate KRas oncogenesis.Comparative Nucleotide-Dependent Interactome Analysis Reveals Shared and Differential Properties of KRas4a and KRas4b.The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.C-terminus Proteolysis and Palmitoylation Cooperate for Optimal Plasma Membrane Localization of RasA in Aspergillus fumigatus.Heteronemin, a marine natural product, sensitizes acute myeloid leukemia cells towards cytarabine chemotherapy by regulating farnesylation of Ras.RAS status in Korean patients with stage III and IV colorectal cancer.Wild-type Kras expands and exhausts hematopoietic stem cells.Role of a non-canonical splice variant of the Helios gene in the differentiation of acute lymphoblastic leukemic T cells.Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor).Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability
P2860
Q24600698-B461585F-F30B-4027-B17A-AD2B4B07F9A3Q26828777-9D08AE86-807D-4D8C-9474-A0574478462BQ31109746-EF1F0629-F5DF-4D98-9B75-B641FCBA00F8Q33839862-BE811468-158A-4F18-B433-BDAEE5CE4A6EQ34091172-2BBE1F65-A8EA-4129-8FB2-868ACA1116BBQ34372571-AE583776-291B-4F9A-B3E8-75C9A0E555F2Q34406138-28D05717-B854-4430-840A-3973A5C6382DQ34438500-E572FBE4-E8D5-4D71-9986-3B44E3844A49Q35083740-3E44172A-CF98-4D40-A963-B85DB18F7DBFQ35940368-C1266B4E-9BF1-45A1-B386-32C0B9793984Q36076132-7316ACD7-1543-4BCE-81C2-09233A5D4021Q36189380-EE40A697-9304-4E42-A5D8-2B4A01C76230Q36278636-2479BB4F-BF53-4313-A657-9580BC82E518Q36352506-22DA4E68-328D-4A2D-B69B-957FA7947D4DQ36416861-8E1CF3B7-336F-4C73-9455-FCBF38FD56B0Q36697241-D9C57848-FF73-4B3F-9646-9A0F2DBF9B10Q36947793-3B200ADE-A216-4F0A-884F-A15323543824Q37137960-7A448227-657B-4014-9D6B-D3C228E9F9BDQ37610817-86EFB85A-D900-4F36-983C-6CC9740B4313Q37822317-4164CFB3-A821-4843-A021-E13B6F7742B0Q38898397-F886EACE-B85C-4830-8E1E-16B6B4E0D025Q39109238-588A66C9-9A2E-4900-8147-4A3326489341Q39437389-F2AA9F9E-6192-493F-9BF8-FF2AC0D5232BQ39618355-81A91E7D-016B-4ACE-904E-2EBE1B81A207Q39670561-662738A9-7AF1-4976-B013-A5DA01B14877Q40001801-4EE9B7B4-8DF0-43EA-A75E-0FF2E4C519B8Q41906135-975BF99C-9498-46CA-AB5E-C73ECF8084A9Q42784309-A0CF220A-2CBA-4B9C-81E6-66253FEB27B4Q43220010-960F14CC-5B37-49F0-889E-863D3FF925A5Q49164077-2F5758FB-858E-4846-A06B-11439E88CBF3Q50893694-763498AD-2F9A-4180-8831-939430CFBB71Q52327318-D582EF06-3D54-466C-B701-AB864AC67FC5Q52714610-35A45940-C073-4442-9333-F20E45AFF240Q53216530-7E9BA8E6-6D82-462C-90E1-401CF623466EQ54976859-3D493247-321E-4879-968F-37925D85F73DQ55074146-BDB90296-BCBD-43EE-B3CC-1205A162A76EQ55492453-1F7C5C8F-23EB-4EA9-8E6F-4E9D3270349AQ58759673-A07F522E-69AC-4C63-87F0-F6B860ED9275
P2860
Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice
@en
Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.
@nl
type
label
Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice
@en
Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.
@nl
prefLabel
Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice
@en
Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.
@nl
P2093
P2860
P1433
P1476
Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice
@en
P2093
Chaitali Parikh
Ramesh Subrahmanyam
Ruibao Ren
P2860
P304
P356
10.1158/0008-5472.CAN-07-0778
P407
P577
2007-08-01T00:00:00Z